ENTX

Entera BioB

Nasdaq / Pharmaceuticals, Biotechnology & Life Sciences

At close

2026-06-02

View Chart

AI scenario view

RankAlpha Sentiment Codex

B+

Bull case

25%

Probability

Target price

$1.90

+52.0% vs current

Most likely

Base case

45%

Probability

Target price

$1.00

-20.0% vs current

B-

Bear case

30%

Probability

Target price

$0.55

-56.0% vs current

AI sentiment snapshot

Latest data as of 2026-05-02

AI commentary

Primary-source tone is constructive around EB613 and the April financing, but the checked evidence still reads as a cautious monitoring setup rather than a confirmed inflection. Reviewed IR materials show March-April 2026 milestone activity, yet no confirmed FDA-response follow-up was found in the checked sources as of May 2, 2026, no meaningful recent trusted-news or analyst-revision set was present to strengthen conviction, and the available peer set is too loose for a standard-conviction relative view.

RankAlpha Sentiment Codex - 2026-05-02

Open full AI memo

Evidence flagged

small-cap biotech peer set is too weak or includes unrelated comparators for a standard-conviction report

Impact

tentative

Confidence

AI events

2026-05-03eventPending FDA feedback on the streamlined EB613 Phase 3 amendmentHigh impact

Entera said it submitted a streamlined Phase 3 protocol, SAP, and extension synopsis for EB613 on March 4, 2026 and anticipated FDA feedback within 60 days; the March 27 business update still pointed to feedback in late April 2026. A confirmed FDA response or protocol alignment would be the cleanest near-term de-risking event, but no checked primary follow-up was found in the reviewed materials as of May 2, 2026 [#PR-2026-03-04] [#10-K-2026-03-27].

2026-11-15catalystEB613 Phase 3 initiation remains the main value driver for late 2026High impact

Management said the planned EB613 study could start in late 2026, with a 750-patient design and topline in 2H 2028, and the April 2026 financing was earmarked to support Phase 3 initiation. However, the 10-K also said existing cash was sufficient only through the middle of Q3 2026 excluding Phase 3 initiation, so actual study start would simultaneously confirm execution and reduce financing doubt [#PR-2026-03-04] [#8-K-2026-04-03] [#10-K-2026-03-27].

2026-12-15catalystEB612 pre-IND/IND progress offers a secondary pipeline checkHigh impact

Beyond EB613, Entera said it intended to accelerate its oral long-acting PTH program for hypoparathyroidism and expected an IND filing in late 2026 with OPKO-related support. This is a real pipeline milestone, but it is clearly secondary to EB613 for current valuation and does not remove near-term funding or execution risk [#10-K-2026-03-27].

View full catalyst timeline

Recommendation

N/A

No formal recommendation provided.

Open AI Memo

As of 2026-05-02 • Updated nightlySource: Internal modelMethodology